7 KILLED, HUNDREDS INJURED AS STRONG QUAKE HITS SULAWESI, INDONESIA
VATICAN: POPE FRANCIS, FORMER POPE BENEDICT BOTH GET COVID-19 VACCINE
AUSTRALIA REBUKES GOOGLE FOR BLOCKING LOCAL CONTENT
JAPAN TO BAN ENTRY OF FOREIGN ATHLETES TO TRAIN AHEAD OF SUMMER OLYMPICS
BIDEN INAUGURATION WILL FEATURE DIVERSE PERFORMANCES INCLUDING LADY GAGA, JENNIFER LOPEZ
COURT ORDERS ARREST OF COPS ACCUSED OF KILLING ARMY MEN IN JOLO
THE PANDEMIC SLAMS PHL VEHICLE SALES IN 2020
CHESS PLAYER WESLEY SO BAGS P11.8M, JOINS WORLD’S TOP ESPORT EARNERS
ZSA ZSA PADILLA FINALLY VISITS THE GRAVE OF ‘COMEDY KING’ DOLPHY AGAIN
DUTERTE: PRESIDENCY JOB NOT FOR A WOMEN

CHINA’S CAS COVID-19 VACINE INDUCES IMMUNE RESPONSE IN MID STAGE TESTS

2 months ago | World | 0 comments

By Xai Reyes

Researchers said a COVID-19 vaccine candidate developed by the Chinese Academy of Science (CAS) was found to be safe and triggered immune responses in early and mid-stage trials.

A late-stage trial of the ZF2001 vaccine, which CAS is developing with a unit of Chongqing Zhifei Biological Products, began last month in China.

It aims to recruit 29,000 people across China, Uzbekistan, Indonesia, Pakistan and Ecuador.

The candidate did not cause serious adverse events, with common mild side-effects including injection pain, redness and swelling, researchers at the Chongqing Zhifei unit, CAS, and other Chinese institutes said in a paper published on Tuesday ahead of peer review.

The combined data from Phase 1 and 2 trials involved 950 healthy Chinese participants aged 18-59.

Low dose and high dose versions were tested, and the Phase 2 study also tested two doses versus three doses for both the low dose and high dose versions.

0 Comments

Submit a Comment

Your email address will not be published.

Social Media